MCID: 8P1002
MIFTS: 39

8p11 Myeloproliferative Syndrome

Categories: Blood diseases, Cancer diseases, Immune diseases, Liver diseases, Rare diseases

Aliases & Classifications for 8p11 Myeloproliferative Syndrome

MalaCards integrated aliases for 8p11 Myeloproliferative Syndrome:

Name: 8p11 Myeloproliferative Syndrome 25
Myeloid and Lymphoid Neoplasms with Fgfr1 Abnormalities 25
Myeloid and Lymphoid Neoplasms with Fgfr1 Rearrangement 71
Chromosome 8p11 Myeloproliferative Syndrome 71
8p11 Stem Cell Leukemia/lymphoma Syndrome 25
Stem Cell Leukemia/lymphoma 25
8p11 Stem Cell Syndrome 25

Classifications:



External Ids:

UMLS 71 C2827362 C3150773

Summaries for 8p11 Myeloproliferative Syndrome

Genetics Home Reference : 25 8p11 myeloproliferative syndrome is a blood cancer that involves different types of blood cells. Blood cells are divided into several groups (lineages) based on the type of early cell from which they are descended. Two of these lineages are myeloid cells and lymphoid cells. Individuals with 8p11 myeloproliferative syndrome can develop both myeloid cell cancer and lymphoid cell cancer. The condition can occur at any age. It usually begins as a myeloproliferative disorder, which is characterized by a high number of white blood cells (leukocytes). Most affected individuals also have an excess of myeloid cells known as eosinophils (eosinophilia). In addition to a myeloproliferative disorder, many people with 8p11 myeloproliferative syndrome develop lymphoma, which is a form of blood cancer that involves lymphoid cells. The cancerous lymphoid cells grow and divide in lymph nodes, forming a tumor that enlarges the lymph nodes. In most cases of 8p11 myeloproliferative syndrome, the cancerous cells are lymphoid cells called T cells. Lymphoma can develop at the same time as the myeloproliferative disorder or later. In most people with 8p11 myeloproliferative syndrome, the myeloproliferative disorder develops into a fast-growing blood cancer called acute myeloid leukemia. The rapid myeloid and lymphoid cell production caused by these cancers results in enlargement of the spleen and liver (splenomegaly and hepatomegaly, respectively). Most people with 8p11 myeloproliferative syndrome have symptoms such as fatigue or night sweats. Some affected individuals have no symptoms, and the condition is discovered through routine blood tests.

MalaCards based summary : 8p11 Myeloproliferative Syndrome, also known as myeloid and lymphoid neoplasms with fgfr1 abnormalities, is related to chromosome 8p11 myeloproliferative syndrome and lymphoblastic lymphoma. An important gene associated with 8p11 Myeloproliferative Syndrome is SCLL (Chromosome 8p11 Myeloproliferative Syndrome), and among its related pathways/superpathways are HIV Life Cycle and Cytokine Signaling in Immune system. The drugs Methotrexate and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include myeloid, lymph node and t cells, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for 8p11 Myeloproliferative Syndrome

Diseases in the 8p11 Myeloproliferative Syndrome family:

Myeloproliferative Syndrome, Transient Myeloproliferative Disease, Autosomal Recessive

Diseases related to 8p11 Myeloproliferative Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Related Disease Score Top Affiliating Genes
1 chromosome 8p11 myeloproliferative syndrome 35.1 SCLL FGFR1
2 lymphoblastic lymphoma 31.1 ZMYM2 FGFR1OP2 FGFR1
3 hypereosinophilic syndrome 30.9 PDGFRB KIT FGFR1
4 acute leukemia 30.1 RUNX1 KIT FLT3 BCR
5 myeloid leukemia 30.0 RUNX1 KIT FLT3 BCR
6 atypical chronic myeloid leukemia 29.8 RUNX1 PDGFRB FGFR1
7 chronic myelomonocytic leukemia 29.3 RUNX1 PDGFRB KIT FLT3
8 leukemia, acute myeloid 29.0 RUNX1 PDGFRB KIT KDR FLT3 FGFR1
9 leukemia, chronic myeloid 28.8 RUNX1 PDGFRB KIT FLT3 FGFR1 BCR
10 myeloproliferative neoplasm 28.7 ZMYM2 RUNX1 PDGFRB MYO18A KIT FLT3
11 hematologic cancer 28.7 RUNX1 PDGFRB KIT KDR FLT3 FGFR1
12 myelodysplastic syndrome 28.6 RUNX1 PDGFRB KIT KDR FLT3
13 lymphocytic leukemia 10.4
14 polykaryocytosis inducer 10.3
15 rare tumor 10.3
16 leukemia 10.2
17 lymphoma, hodgkin, classic 10.2
18 lymphoma, non-hodgkin, familial 10.2
19 leukemia, acute lymphoblastic 10.2
20 peripheral t-cell lymphoma 10.2
21 thrombocytopenia 10.2
22 myelodysplastic/myeloproliferative neoplasm 10.2
23 monocytic leukemia 10.2
24 myeloid sarcoma 10.2
25 acute myeloblastic leukemia with maturation 10.2 KIT FLT3
26 primary hypereosinophilic syndrome 10.2 PDGFRB FGFR1
27 lymphoma 10.1
28 pulmonary vein stenosis 10.1 KIT KDR
29 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.1 ZMYM2 PDGFRB FGFR1
30 fibrosarcoma of bone 10.0 KIT KDR
31 myeloid and lymphoid neoplasms associated with fgfr1 abnormalities 10.0 ZMYM2 FLT3 FGFR1OP2 FGFR1
32 precursor t-cell acute lymphoblastic leukemia 9.9
33 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 9.9 PDGFRB KIT FGFR1
34 hypereosinophilic syndrome, idiopathic 9.9 PDGFRB KIT
35 exanthem 9.9 KIT KDR FLT3
36 systemic mastocytosis 9.8 PDGFRB KIT FGFR1
37 leukemia, acute lymphoblastic 3 9.8 RUNX1 FLT3 BCR
38 acute myeloid leukemia with t(8;21)(q22;q22) translocation 9.8 RUNX1 KIT FLT3
39 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 9.8 RUNX1 KIT FLT3
40 core binding factor acute myeloid leukemia 9.8 RUNX1 KIT FLT3
41 vascular cancer 9.8 PDGFRB KIT KDR
42 cebpa-associated familial acute myeloid leukemia 9.8 RUNX1 KIT FLT3
43 chronic eosinophilic leukemia 9.7 PDGFRB KIT FLT3 FGFR1
44 chronic leukemia 9.7 PDGFRB KIT FLT3 BCR
45 mastocytosis 9.7 PDGFRB KIT FLT3 FGFR1
46 frontal convexity meningioma 9.7 PDGFRB FGF1
47 gliosarcoma 9.6 PDGFRB KDR FGFR1
48 blood platelet disease 9.5 RUNX1 KIT FLT3
49 gastrointestinal stromal tumor 9.4 PDGFRB KIT KDR FLT3
50 pancreatic adenocarcinoma 9.4 PDGFRB KIT KDR FGFR1 FGF1

Graphical network of the top 20 diseases related to 8p11 Myeloproliferative Syndrome:



Diseases related to 8p11 Myeloproliferative Syndrome

Symptoms & Phenotypes for 8p11 Myeloproliferative Syndrome

GenomeRNAi Phenotypes related to 8p11 Myeloproliferative Syndrome according to GeneCards Suite gene sharing:

26 (show all 41)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 10.16 FLT3
2 Decreased viability GR00221-A-1 10.16 FGFR1 FLT3 KDR KIT PDGFRB
3 Decreased viability GR00221-A-2 10.16 FGFR1 KDR
4 Decreased viability GR00221-A-3 10.16 KDR PDGFRB
5 Decreased viability GR00221-A-4 10.16 FLT3 KDR PDGFRB
6 Decreased viability GR00301-A 10.16 KIT
7 Decreased viability GR00342-S-1 10.16 PDGFRB
8 Decreased viability GR00402-S-2 10.16 FGFR1 FLT3 KDR KIT PDGFRB
9 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.88 BCR
10 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.88 KIT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.88 TPR
12 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.88 BCR
13 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.88 TPR
14 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.88 BCR
15 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.88 TRIM24
16 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.88 BCR
17 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.88 KDR TRIM24
18 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.88 TRIM24
19 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.88 KIT
20 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.88 KIT
21 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.88 BCR
22 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.88 BCR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.88 KIT
24 Increased shRNA abundance (Z-score > 2) GR00366-A-173 9.88 TRIM24
25 Increased shRNA abundance (Z-score > 2) GR00366-A-2 9.88 BCR
26 Increased shRNA abundance (Z-score > 2) GR00366-A-205 9.88 TPR
27 Increased shRNA abundance (Z-score > 2) GR00366-A-215 9.88 BCR
28 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.88 BCR
29 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.88 KIT
30 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.88 KDR
31 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.88 KIT
32 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.88 TRIM24
33 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.88 KDR TPR TRIM24
34 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.88 BCR
35 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.88 BCR KDR KIT TPR TRIM24
36 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.88 KIT
37 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.88 KIT
38 Decreased substrate adherent cell growth GR00193-A-1 9.73 KIT
39 Decreased substrate adherent cell growth GR00193-A-2 9.73 KIT
40 Decreased substrate adherent cell growth GR00193-A-4 9.73 FGFR1 FLT3 KDR KIT
41 Increased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.26 FGFR1 FLT3 KDR PDGFRB

MGI Mouse Phenotypes related to 8p11 Myeloproliferative Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.36 BCR FGF1 FGFR1 FGFR1OP FLT3 KDR

Drugs & Therapeutics for 8p11 Myeloproliferative Syndrome

Drugs for 8p11 Myeloproliferative Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
2
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
3
leucovorin Approved Phase 2 58-05-9 6006 143
4
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
5
Lenograstim Approved, Investigational Phase 2 135968-09-1
6
Clofarabine Approved, Investigational Phase 2 123318-82-1 119182
7
Busulfan Approved, Investigational Phase 2 55-98-1 2478
8
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
9
Mesna Approved, Investigational Phase 2 3375-50-6 598
10
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
11 Thymoglobulin Phase 2
12 Alkylating Agents Phase 2
13 Folic Acid Antagonists Phase 2
14 Dermatologic Agents Phase 2
15 Folate Phase 2
16 Vitamin B Complex Phase 2
17 Vitamin B9 Phase 2
18 Antilymphocyte Serum Phase 2
19 Immunosuppressive Agents Phase 2
20 Antirheumatic Agents Phase 2
21 Protective Agents Phase 2
22 Adjuvants, Immunologic Phase 2
23 Antimetabolites Phase 2
24 Immunologic Factors Phase 2
25 Calcineurin Inhibitors Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies Completed NCT00857389 Phase 2 Thiotepa;Clofarabine;Busulfan;Thymoglobulin (ATG);G-CSF (Filgrastim);Tacrolimus;Methotrexate;Cyclophosphamide;Mesna

Search NIH Clinical Center for 8p11 Myeloproliferative Syndrome

Genetic Tests for 8p11 Myeloproliferative Syndrome

Anatomical Context for 8p11 Myeloproliferative Syndrome

MalaCards organs/tissues related to 8p11 Myeloproliferative Syndrome:

40
Myeloid, Lymph Node, T Cells, Liver, Spleen, Testes, Bone

Publications for 8p11 Myeloproliferative Syndrome

Articles related to 8p11 Myeloproliferative Syndrome:

(show top 50) (show all 103)
# Title Authors PMID Year
1
Functional characterization of two rare BCR-FGFR1+ leukemias. 61
31980503 2020
2
Rac1/2 activation promotes FGFR1 driven leukemogenesis in stem cell leukemia/lymphoma syndrome. 61
31221776 2020
3
The Ems Syndrome (8P11/12 Myeloproliferative Syndrome) or Human Stem Cell Leukemia/Lymphoma Syndrome-A Unique and Rare Case. 61
31979932 2020
4
Distinct signaling programs associated with progression of FGFR1 driven leukemia in a mouse model of stem cell leukemia lymphoma syndrome. 61
30439482 2019
5
DNA methyltransferase 1-mediated CpG methylation of the miR-150-5p promoter contributes to fibroblast growth factor receptor 1-driven leukemogenesis. 61
31628193 2019
6
[8p11 myeloproliferative syndrome with t(8;22) (p11; q11): a case report]. 61
31856441 2019
7
[Myeloid/lymphoid neoplasms with eosinophilia and FGFR1 rearrangement: 5 cases report and literatures review]. 61
31775485 2019
8
Critical individual roles of the BCR and FGFR1 kinase domains in BCR-FGFR1-driven stem cell leukemia/lymphoma syndrome. 61
31525277 2019
9
Oncogenic fusion protein BCR-FGFR1 requires BCR-mediated oligomerization and chaperonin Hsp90 for activation. 61
31439673 2019
10
[8p11 myeloproliferative syndrome with CEP110-FGFR1 fusion in a child]. 61
30934206 2019
11
Allogeneic hematopoietic stem cell transplantation for 8p11 myeloproliferative syndrome with BCR-FGFR1 gene rearrangement: a case report and literature review. 61
30087462 2019
12
[The 8p11 myeloproliferative syndrome: a review of recent literature]. 61
31597839 2019
13
Loss of the BCR-FGFR1 GEF Domain Suppresses RHOA Activation and Enhances B-Lymphomagenesis in Mice. 61
30413411 2019
14
[Clinical and molecular features of one case of 8p11 myeloproliferative syndrome with t(8;17) (p11; q24)]. 61
30612409 2018
15
FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome. 61
29720732 2018
16
8p11 Myeloproliferative syndrome with t(8;22)(p11;q11): A case report. 61
30116393 2018
17
miR-339 Promotes Development of Stem Cell Leukemia/Lymphoma Syndrome via Downregulation of the BCL2L11 and BAX Proapoptotic Genes. 61
29735550 2018
18
8p11 Stem Cell Leukemia/Lymphoma Syndrome without Myeloproliferation: A Rare Clinical Entity. 61
29622897 2018
19
Precursor T-Lymphoblastic Lymphoma Associated with t(8;9)(p11.2;q33): A Case Report and Review of the Literature. 61
29614500 2018
20
A Case of Myeloproliferative Neoplasm with BCR-FGFR1 Rearrangement: Favorable Outcome after Haploidentical Allogeneic Transplantation. 61
30647980 2018
21
Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas. 61
28646488 2017
22
Primary cells in BCR/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib. 61
28881484 2017
23
Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase. 61
28551329 2017
24
Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPR‑FGFR1 fusion. 61
28138694 2017
25
Diagnostic application of next-generation sequencing in ZMYM2-FGFR1 8p11 myeloproliferative syndrome: A case report. 61
27415155 2016
26
Development of ZMYM2-FGFR1 driven AML in human CD34+ cells in immunocompromised mice. 61
27005999 2016
27
8p11 myeloproliferative syndrome: diagnostic challenges and pitfalls. 61
27569099 2016
28
8p11 Myeloproliferative Syndrome with t(7;8) Translocation Presenting as Acute Myeloid Leukemia: A Case Report and Literature Review. 61
27188774 2016
29
Restored expression of vitamin D receptor and sensitivity to 1,25-dihydroxyvitamin D3 in response to disrupted fusion FOP2-FGFR1 gene in acute myeloid leukemia cells. 61
26839680 2016
30
Functional characterization, localization, and inhibitor sensitivity of the TPR-FGFR1 fusion in 8p11 myeloproliferative syndrome. 61
26391436 2016
31
[8p11 myeloproliferative syndrome with CEP110-FGFR1 fusion in a patient]. 61
26418991 2015
32
[Clinical and gene involved of one case of 8p11 myeloproliferative syndrome with ins(13;8)(q12;p11p23)]. 61
25916288 2015
33
8p11 myeloproliferative syndrome: a case report of this rare clinical entity. 61
25885151 2015
34
8p11 myeloproliferative syndrome with t(1;8)(q25;p11.2): a case report and review of the literature. 61
25227135 2015
35
Screening of drugs to treat 8p11 myeloproliferative syndrome using patient-derived induced pluripotent stem cells with fusion gene CEP110-FGFR1. 61
25803811 2015
36
Molecular identification of a TPR-FGFR1 fusion transcript in an adult with myeloproliferative neoplasm, T-lymphoblastic lymphoma, and a t(1;8)(q25;p11.2). 61
25037443 2014
37
FGF receptors: cancer biology and therapeutics. 61
23696246 2014
38
[8p11 myeloproliferative syndrome cured by allogeneic hematopoietic stem cell transplantation: two case reports and literature review]. 61
24343089 2013
39
Quantitative polymerase chain reaction detection of CEP110-FGFR1 fusion gene in a patient with 8p11 myeloproliferative syndrome. 61
23327291 2013
40
[8p11 myeloproliferative syndrome]. 61
23998615 2013
41
A case of acute myelogenous leukaemia characterised by the BCR-FGFR1 translocation. 61
23519513 2013
42
Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome. 61
22875613 2013
43
A case of 8p11 myeloproliferative syndrome with BCR-FGFR1 gene fusion presenting with trilineage acute leukemia/lymphoma, successfully treated by cord blood transplantation. 61
23171834 2013
44
Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities. 61
22781593 2013
45
Identification of a novel partner gene, TPR, fused to FGFR1 in 8p11 myeloproliferative syndrome. 61
22619110 2012
46
Favorable outcome of allogeneic hematopoietic cell transplantation for 8p11 myeloproliferative syndrome associated with BCR-FGFR1 gene fusion. 61
22106025 2012
47
A novel t(1;8)(q25;p11.2) translocation associated with 8p11 myeloproliferative syndrome. 61
21848523 2012
48
Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases. 61
21937681 2011
49
Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease. 61
21527531 2011
50
The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11). 61
21330321 2011

Variations for 8p11 Myeloproliferative Syndrome

Expression for 8p11 Myeloproliferative Syndrome

Search GEO for disease gene expression data for 8p11 Myeloproliferative Syndrome.

Pathways for 8p11 Myeloproliferative Syndrome

Pathways related to 8p11 Myeloproliferative Syndrome according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.47 ZMYM2 TRIM24 TPR PDGFRB MYO18A KIT
2
Show member pathways
13.22 TPR PDGFRB KIT FLT3 FGFR1 FGF1
3
Show member pathways
13.17 PDGFRB KIT KDR FLT3 FGFR1 FGF1
4
Show member pathways
13.13 PDGFRB KIT KDR FLT3 FGFR1 FGF1
5
Show member pathways
12.92 PDGFRB KIT KDR FGFR1 FGF1
6
Show member pathways
12.9 PDGFRB KIT KDR FGFR1 FGF1
7
Show member pathways
12.88 PDGFRB KIT KDR FLT3 FGFR1 FGF1
8
Show member pathways
12.82 PDGFRB KIT KDR FLT3 FGFR1
9
Show member pathways
12.75 TPR RUNX1 PDGFRB KIT FLT3 FGFR1
10 12.67 PDGFRB KIT KDR FLT3 FGFR1 FGF1
11
Show member pathways
12.62 PDGFRB KIT KDR FLT3 FGFR1 FGF1
12 12.58 TPR RUNX1 PDGFRB KIT FLT3 FGFR1
13
Show member pathways
12.36 TRIM24 PDGFRB KDR FGFR1
14
Show member pathways
12.31 PDGFRB KIT KDR FLT3 FGFR1 FGF1
15
Show member pathways
12.17 PDGFRB KIT KDR FGFR1 FGF1
16
Show member pathways
12.13 KDR FGFR1OP2 FGFR1OP FGFR1
17 11.92 RUNX1 PDGFRB KDR
18 11.87 PDGFRB KIT KDR FLT3 FGFR1 FGF1
19
Show member pathways
11.81 ZMYM2 TRIM24 MYO18A FGFR1OP2 FGFR1OP FGFR1
20 11.76 PDGFRB KDR FGFR1 FGF1
21
Show member pathways
11.69 PDGFRB KIT KDR FLT3 FGFR1
22 11.62 PDGFRB KIT FLT3 FGFR1
23
Show member pathways
11.48 PDGFRB KIT BCR
24 11.37 PDGFRB KDR FGFR1 FGF1
25
Show member pathways
11.24 PDGFRB KIT KDR FLT3
26
Show member pathways
11.23 ZMYM2 TRIM24 MYO18A FGFR1OP2 FGFR1OP FGFR1
27 10.93 PDGFRB KIT KDR FLT3 FGFR1 FGF1

GO Terms for 8p11 Myeloproliferative Syndrome

Cellular components related to 8p11 Myeloproliferative Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.9 ZMYM2 TRIM24 RUNX1 NSMAF FLT3 FGFR1OP2
2 cytoplasm GO:0005737 9.8 TRIM24 TPR PDGFRB NSMAF MYO18A KIT
3 receptor complex GO:0043235 9.02 PDGFRB KIT KDR FLT3 FGFR1

Biological processes related to 8p11 Myeloproliferative Syndrome according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 10 PDGFRB KIT KDR FLT3 FGFR1 BCR
2 protein phosphorylation GO:0006468 9.98 TRIM24 PDGFRB KIT KDR FLT3 FGFR1
3 positive regulation of cell proliferation GO:0008284 9.91 PDGFRB KIT KDR FLT3 FGFR1OP FGFR1
4 MAPK cascade GO:0000165 9.88 PDGFRB KIT FLT3 FGFR1 FGF1
5 cell migration GO:0016477 9.87 PDGFRB MYO18A KDR FGFR1
6 positive regulation of cell migration GO:0030335 9.85 PDGFRB KIT KDR FGFR1OP FGF1
7 positive regulation of protein kinase B signaling GO:0051897 9.84 PDGFRB KIT FGFR1 FGF1
8 positive regulation of MAPK cascade GO:0043410 9.8 KIT KDR FLT3 FGFR1
9 hemopoiesis GO:0030097 9.75 RUNX1 KIT FLT3
10 hematopoietic progenitor cell differentiation GO:0002244 9.73 PDGFRB KIT FLT3
11 peptidyl-tyrosine phosphorylation GO:0018108 9.72 PDGFRB KIT KDR FLT3 FGFR1
12 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.69 PDGFRB KIT FLT3
13 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.65 PDGFRB KIT KDR FLT3 FGFR1
14 vascular endothelial growth factor signaling pathway GO:0038084 9.6 KDR FLT3
15 embryonic hemopoiesis GO:0035162 9.59 KIT KDR
16 organ induction GO:0001759 9.58 FGFR1 FGF1
17 positive regulation of phospholipase C activity GO:0010863 9.58 PDGFRB KIT FGFR1
18 myeloid progenitor cell differentiation GO:0002318 9.55 KIT FLT3
19 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.55 PDGFRB KIT KDR FLT3 FGFR1
20 positive regulation of MAP kinase activity GO:0043406 9.35 PDGFRB KIT FLT3 FGFR1 FGF1
21 protein autophosphorylation GO:0046777 9.17 TRIM24 PDGFRB KIT KDR FLT3 FGFR1

Molecular functions related to 8p11 Myeloproliferative Syndrome according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.31 ZMYM2 TRIM24 TPR RUNX1 PDGFRB NSMAF
2 transferase activity GO:0016740 10.04 TRIM24 PDGFRB KIT KDR FLT3 FGFR1
3 protein homodimerization activity GO:0042803 9.95 TPR KIT FLT3 FGFR1OP2 FGFR1OP FGFR1
4 ATP binding GO:0005524 9.86 RUNX1 PDGFRB MYO18A KIT KDR FLT3
5 kinase activity GO:0016301 9.8 PDGFRB KIT KDR FLT3 FGFR1 BCR
6 nucleotide binding GO:0000166 9.77 PDGFRB MYO18A KIT FLT3 FGFR1
7 protein kinase activity GO:0004672 9.63 TRIM24 PDGFRB KIT KDR FLT3 FGFR1
8 vascular endothelial growth factor binding GO:0038085 9.46 PDGFRB KDR
9 vascular endothelial growth factor-activated receptor activity GO:0005021 9.43 KDR FLT3
10 protein tyrosine kinase activity GO:0004713 9.35 PDGFRB KIT KDR FLT3 FGFR1
11 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.02 PDGFRB KIT KDR FLT3 FGFR1

Sources for 8p11 Myeloproliferative Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....